RemeGen Allocates Additional RMB50.00 Million to HTSC Wealth Management Products, Raising Total Deployment to RMB538.00 Million

Bulletin Express
05/20

RemeGen Co., Ltd. (RemeGen) disclosed that on 20 May 2026 it signed two new agreements—HTSC Wealth Management Product Agreement No. 7 and No. 8—with Huatai Securities Co., Ltd. (HTSC), committing a further RMB20.00 million and RMB30.00 million, respectively, of idle self-owned funds to medium-risk wealth management products.

• Agreement No. 7: “Xiamen Trust – Hongyun Xiangtai No. 11 Asset Management Trust Product” – Product type: Fixed-income collective fund trust plan – Principal: RMB20.00 million – Tenor: ~36 months; early termination at trustee’s discretion – Risk rating: Medium; yield tied to market performance – Investment focus: Consumer loan assets via revolving purchase

• Agreement No. 8: “Shengxinxiang – Huatai WEFUND Private FOF 1067 Separate Asset Management Plan” – Product type: Mixed private FOF – Principal: RMB30.00 million – Tenor: 10 years with subscriber-driven exit; early termination at administrator’s discretion – Risk rating: Medium; yield tied to market performance – Investment focus: Financial products and cash-type assets

Including the latest tranche, RemeGen has channelled RMB538.00 million into eight HTSC-managed products since 14 May 2026: • 14 May: RMB60.00 million (No. 1), RMB75.00 million (No. 2), RMB102.00 million (No. 3), RMB216.00 million (No. 4) • 19 May: RMB15.00 million (No. 5), RMB20.00 million (No. 6) • 20 May: RMB20.00 million (No. 7), RMB30.00 million (No. 8)

The Board previously authorised up to RMB2.50 billion for cash management using idle funds at its 36th meeting on 27 March 2026. Post-transaction, around RMB1.96 billion of the approved limit remains unutilised.

Under Hong Kong Listing Rule 14.22, the eight agreements—concluded with the same financial institution within a 12-month period—are aggregated. As one of the applicable percentage ratios exceeds 5% but all remain below 25%, the series of purchases constitutes a discloseable transaction, triggering reporting and announcement obligations under Chapter 14 of the Listing Rules.

RemeGen states that the medium-risk products, offering returns above comparable bank time deposits, aim to enhance the yield on its surplus cash while maintaining prudent risk control. HTSC is an independent third-party securities company listed on both the Shanghai and Hong Kong stock exchanges, providing wealth management and other financial services.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10